Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

Nature Communications

Volumn 7, Issue , 2016, Pages

  Mitchell, Jonathan S ^a   Li, Ni ^a   Weinhold, Niels ^b,c   Försti, Asta ^d,e   Ali, Mina ^f   Van Duin, Mark ^g   Thorleifsson, Gudmar ^h   Johnson, David C ^a   Chen, Bowang ^d   Halvarsson, Britt Marie ^f   Gudbjartsson, Daniel F ^h,i   Kuiper, Rowan ^g   Stephens, Owen W ^b   Bertsch, Uta ^c,j   Broderick, Peter ^a   Campo, Chiara ^d   Einsele, Hermann ^k   Gregory, Walter A ^l   Gullberg, Urban ^f   Henrion, Marc ^a   Hillengass, Jens ^c   Hoffmann, Per ^m,n   Jackson, Graham H ^o   Johnsson, Ellinor ^f   Jöud, Magnus ^f,p   Kristinsson, Sigurur Y ^q   Lenhoff, Stig ^r   Lenive, Oleg ^a   Mellqvist, Ulf Henrik ^s   Migliorini, Gabriele ^a   Nahi, Hareth ^t   Nelander, Sven ^u   Nickel, Jolanta ^c   Nöthen, Markus M ^m   Rafnar, Thorunn ^h   Ross, Fiona M ^v   Da Silva Filho, Miguel Inacio ^d   Swaminathan, Bhairavi ^f   Thomsen, Hauke ^d   Turesson, Ingemar ^r   Vangsted, Annette ^w   Vogel, Ulla ^x   Waage, Anders ^y   Walker, Brian A ^b   Wihlborg, Anna Karin ^f   Broyl, Annemiek ^g   Davies, Faith E ^b   Thorsteinsdottir, Unnur ^h,i   Langer, Christian ^z   Hansson, Markus ^f,r   Kaiser, Martin ^a   Sonneveld, Pieter ^g   Stefansson, Kari ^h   Morgan, Gareth J ^b   Goldschmidt, Hartmut ^c,j   Hemminki, Kari ^d,e   Nilsson, Björn ^f,p,aa   Houlston, Richard S ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g ERASMUS MC CANCER INSTITUTE   (Netherlands)

^h DECODE GENETICS   (Iceland)

ⁱ UNIVERSITY OF ICELAND   (Iceland)

^j National Center of Tumor Diseases   (Germany)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l UNIVERSITY OF LEEDS   (United Kingdom)

^m UNIVERSITY OF BONN   (Germany)

ⁿ UNIVERSITY OF BASEL   (Switzerland)

^o ROYAL VICTORIA INFIRMARY   (United Kingdom)

^p Clinical Immunology and Transfusion Medicine   (Sweden)

^q LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^r LUND UNIVERSITY HOSPITAL   (Sweden)

^s SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^t KAROLINSKA INSTITUTE   (Sweden)

^u UPPSALA UNIVERSITY   (Sweden)

^v UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^w Mental Health Services CPH   (Denmark)

^x NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^y NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^z UNIVERSITY OF ULM   (Germany)

^aa BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; COLON CANCER ASSOCIATED TRANSCRIPT 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; JUMONJI AT RICH INTERACTIVE DOMAIN 2 PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE DEPENDENT RAC EXCHANGE FACTOR 1; RING FINGER WD DOMAIN 3 PROTEIN; SNF RELATED MATRIX ASSOCIATED ACTIN DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY D MEMBER 3 PROTEIN; TRANSCRIPTION FACTOR GATA; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING ADAPTOR WITH COILEDCOIL REGION PROTEIN; ATG5 PROTEIN, HUMAN; AUTOPHAGY RELATED PROTEIN 5; CCAT1 LONG NONCODING RNA, HUMAN; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; GUANINE NUCLEOTIDE EXCHANGE FACTOR; JARID2 PROTEIN, HUMAN; LONG UNTRANSLATED RNA; POLYCOMB REPRESSIVE COMPLEX 2; PREX1 PROTEIN, HUMAN; RFWD3 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMARCD3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE; WAC PROTEIN, HUMAN;

BIOLOGICAL ANALYSIS; GENETIC ANALYSIS; GENOME; HEALTH RISK; HERITABILITY; META-ANALYSIS; PLASMA; TUMOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC LYMPHATIC LEUKEMIA; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; GLIOMA; HODGKIN DISEASE; HUMAN; INTRON; LUNG CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CANCER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE TRAIT LOCUS; REPLICATION STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AUTOPHAGY-RELATED PROTEIN 5; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P18; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MULTIPLE MYELOMA; POLYCOMB REPRESSIVE COMPLEX 2; RNA, LONG NONCODING; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84977123396     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12050     Document Type: Article

References (70)

1. Morgan, G. J. et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 28, 518-524 (2014).
2. Chubb, D. et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221-1225 (2013).
3. Weinhold, N. et al. The CCND1 c.870G4A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522-525 (2013).
4. Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 44, 58-61 (2012).
5. Swaminathan, B. et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat. Commun. 6, 7213 (2015).
6. Mitchell, J. S. et al. Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Sci. Rep. 5, 12473 (2015).
7. Erickson, S. W. et al. Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. Blood 124, 2001-2003 (2014).
8. Genomes Project, C et al. A map of human genome variation from populationscale sequencing. Nature 467, 1061-1073 (2010).
9. Huang, J. et al. Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. Nat. Commun. 6, 8111 (2015).
10. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 47, 435-444 (2015).
11. Fletcher, O. & Houlston, R. S. Architecture of inherited susceptibility to common cancer. Nat. Rev. Cancer 10, 353-361 (2010).
12. Cerhan, J. R. et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat. Genet. 46, 1233-1238 (2014).
13. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 42, 1126-1130 (2010).
14. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132-136 (2010).
15. Sherborne, A. L. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 42, 492-494 (2010).
16. Joachim, J., Wirth, M., McKnight, N. C. & Tooze, S. A. Coiling up with SCOC and WAC: two new regulators of starvation-induced autophagy. Autophagy 8, 1397-1400 (2012).
17. Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665-1680 (2014).
18. Gaulton, K. J. et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat. Genet. 47, 1415-1425 (2015).
19. Tatetsu, H. et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res. 67, 5328-5336 (2007).
20. Jia, L. et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 5, e1000597 (2009).
21. Ahmadiyeh, N. et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc, Natl Acad. Sci. USA 107, 9742-9746 (2010).
22. Xiang, J. F. et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 24, 513-531 (2014).
23. Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214-1218 (2016).
24. Cenci, S. Autophagy a new determinant of plasma cell differentiation and antibody responses. Mol. Immunol. 62, 289-295 (2014).
25. Pengo, N. et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat. Immunol. 14, 298-305 (2013).
26. Fu, X. et al. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc. Natl Acad. Sci. USA 107, 4579-4584 (2010).
27. Chung, C. C. et al. Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat. Genet. 45, 680-685 (2013).
28. Kinkel, S. A. et al. Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2. Blood 125, 1890-1900 (2015).
29. Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56-e65 (2010).
30. Pawlyn, C., Kaiser, M. F., Davies, F. E. & Morgan, G. J. Current and potential epigenetic targets in multiple myeloma. Epigenomics 6, 215-228 (2014).
31. Toh, P. P. et al. Myc inhibition impairs autophagosome formation. Hum. Mol. Genet. 22, 5237-5248 (2013).
32. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
33. Ocio, E. M., Mateos, M. V., Maiso, P., Pandiella, A. & San-Miguel, J. F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 9, 1157-1165 (2008).
34. Zheng, H. F. et al. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature 526, 112-117 (2015).
35. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
36. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
37. Clayton, D. G. et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243-1246 (2005).
38. Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2, e190 (2006).
39. Liu, J. Z. et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 42, 436-440 (2010).
40. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002).
41. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genomewide complex trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011).
42. Eisen, T., Matakidou, A., Houlston, R. & Consortium, G. Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC Cancer 8, 244 (2008).
43. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305-1309 (2007).
44. Chiecchio, L. et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20, 1610-1617 (2006).
45. Neben, K. et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95, 1150-1157 (2010).
46. Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).
47. Goldschmidt, H. et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann. Hematol. 82, 654-659 (2003).
48. Merz, M. et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica 100, 964-969 (2015).
49. Morgan, G. J. et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97, 442-450 (2012).
50. Morgan, G. J. et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res. 19, 6030-6038 (2013).
51. Johnson, D. C. et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat. Commun. 7, 10290 (2016).
52. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat. Protoc. 7, 500-507 (2012).
53. Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-1089 (2012).
54. Westra, H. J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238-1243 (2013).
55. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
56. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790-1797 (2012).
57. Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272-276 (2009).
58. de Souza, N. The ENCODE project. Nat. Methods 9, 1046 (2012).
59. Cooper, G. M. et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 15, 901-913 (2005).
60. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
61. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
62. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
63. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
64. Jager, R. et al. Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat. Commun. 6, 6178 (2015).
65. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
66. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. Genome-wide complex trait analysis (GCTA): methods, data analyses, and interpretations. Methods Mol. Biol. 1019, 215-236 (2013).
67. Yang, J. et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 43, 519-525 (2011).
68. Lu, Y. et al. Most common 'sporadic' cancers have a significant germline genetic component. Hum. Mol. Genet. 23, 6112-6118 (2014).
69. Lee, S. H. et al. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum. Mol. Genet. 22, 832-841 (2013).
70. Scales, M., Jager, R., Migliorini, G., Houlston, R. S. & Henrion, M. Y. visPIG-a web tool for producing multi-region, multi-track, multi-scale plots of genetic data. PLoS ONE 9, e107497 (2014).